Ardelyx CEO expresses gratitude towards collaboration partner Fosun Pharma for their impressive clinical results, which have played a crucial role in the acceptance of the NDA. The company looks forward to continuing their partnership with Fosun Pharma as they work together to make this innovative treatment available to patients.
As part of their agreement, Ardelyx has already received an upfront payment of $12 million from Fosun Pharma. In addition, they are eligible for further milestone payments and royalty payments based on net sales. Fosun Pharma holds exclusive rights to market and sell tenapanor in China, Hong Kong, and Macau.
Founded with a mission to develop groundbreaking therapies for cardiorenal diseases, Ardelyx is dedicated to improving the lives of patients.